Aytu Biopharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is headquartered in Denver, Colorado.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-12 |
2024-09 |
0 |
N/A |
N/A |
N/A |
2024-09-26 |
2024-06 |
0 |
-0.82 |
N/A |
N/A |
2024-05-15 |
2024-03 |
0 |
-0.52 |
N/A |
N/A |
2024-02-14 |
2023-12 |
0 |
-0.04 |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-1.48 |
N/A |
N/A |
2023-09-27 |
2023-06 |
0 |
0.16 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-08 |
Maxim Group |
Upgrade |
|
Buy |
2023-05-30 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-04-15 |
CANTRELL GARY V. |
Director |
204.09K |
Stock Award(Grant) |
2023-06-13 |
DISBROW JOSHUA R. |
Chief Executive Officer |
71.59K |
Purchase |
2023-08-10 |
DOCKERY CARL C |
Director |
8.94K |
Stock Award(Grant) |
2021-04-07 |
HECHT BETH P |
Director |
9.05K |
Stock Award(Grant) |
2023-08-15 |
JAIN ABHINAV |
Director |
8.00K |
Stock Award(Grant) |
2023-08-10 |
LIU VIVIAN H |
Director |
1.84K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Nantahala Capital Management, LLC |
1.09M |
1.74M |
19.65% |
2023-06-29 |
Stonepine Capital Management, LLC |
472.37K |
755.79K |
8.54% |
2023-06-29 |
Renaissance Technologies, LLC |
57.32K |
91.72K |
1.04% |
2023-06-29 |
Blackrock Inc. |
24.06K |
38.49K |
0.44% |
2023-06-29 |
Acadian Asset Management. LLC |
22.54K |
36.06K |
0.41% |
2023-06-29 |
Prudential Financial, Inc. |
19.58K |
31.32K |
0.35% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
9.99K |
15.99K |
0.18% |
2023-05-30 |
Fidelity Extended Market Index Fund |
8.71K |
14.55K |
0.16% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
1.59K |
2.66K |
0.03% |
2023-05-30 |
Fidelity Total Market Index Fund |
1.59K |
2.65K |
0.03% |
2023-08-30 |
iShares Core S&P Total U.S. Stock Market ETF |
1.27K |
2.15K |
0.02% |
Split |
Date |
1 : 20 |
2023-01-06 |
1 : 10 |
2020-12-09 |
1 : 20 |
2018-08-13 |
1 : 20 |
2017-08-29 |
1 : 12 |
2016-07-01 |
82 : 1000 |
2015-06-10 |